Clinical pharmacokinetics of imatinib mesylate

被引：0
|
作者：
Levêque, D
Maloisel, F
机构：
[1] Hop Hautepierre, F-67000 Strasbourg, France
[2] Inst Bacteriol, F-67000 Strasbourg, France
[3] Hop Civil, Dept Hematol & Oncol, F-67000 Strasbourg, France
来源：
IN VIVO | 2005年 / 19卷 / 01期
关键词：
imatinib mesylate; pharmacokinetics;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The review presents the clinical pharmacokinetics of imatinib mesylate. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed.
引用
收藏
页码：77 / 84
页数：8
相关论文
共 50 条
  • [41] Imatinib mesylate in metastatic chordoma
    Kunitz, A.
    Gebauer, B.
    Sturm, I
    ONKOLOGIE, 2010, 33 : 177 - 177
  • [42] Imatinib mesylate and cardiac function
    Luciano, L.
    Cerchione, C.
    Becchimanzi, C.
    Pane, F.
    Rotoli, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 182 - 182
  • [43] An evaluation of the cardiotoxicity of imatinib mesylate
    Ribeiro, Antonio Luiz
    Marcolino, Milena Soriano
    Bittencourt, Henrique N. S.
    Barbosa, Marcia M.
    Nunes, Maria do Carmo P.
    Xavier, Vitor Fonseca
    Clementino, NeIrna C. D.
    LEUKEMIA RESEARCH, 2008, 32 (12) : 1809 - 1814
  • [44] Mechanisms of resistance to imatinib mesylate
    Roche-Lestienne, Catherine
    Preudhomme, Claude
    HEMATOLOGIE, 2006, 12 : 11 - 18
  • [45] Clinical and molecular response to imatinib mesylate in myeloproliferative hypereosinophilic syndrome.
    Robyn, J
    Akin, C
    Noel, P
    Brown, M
    Law, M
    Metcalfe, D
    Dunbar, C
    Nutman, T
    Klion, A
    BLOOD, 2003, 102 (11) : 922A - 922A
  • [46] Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects
    Na, Joo Young
    Huh, Ki Young
    Yu, Kyung-Sang
    Hyon, Joon Young
    Koo, Hye Cheong
    Lee, Jong Ho
    You, Ji Chang
    Chung, Jae-Yong
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (05): : 1123 - 1130
  • [47] The influence of St. John's Wort on the pharmacokinetics and protein binding of imatinib mesylate.
    Bullock, JM
    Smith, PF
    Haas, C
    Booker, BM
    Berenson, C
    Jusko, WJ
    PHARMACOTHERAPY, 2003, 23 (10): : 1352 - 1352
  • [48] Potential clinical application of imatinib mesylate in patients with leukemic large granular lymphocytes
    Yang, Jun
    Loughran, Thomas P.
    LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1834 - 1835
  • [49] Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases
    Eklund, KK
    Joensuu, H
    ANNALS OF MEDICINE, 2003, 35 (05) : 362 - 367
  • [50] Imatinib mesylate - A viewpoint by Ian Judson
    Judson, I
    DRUGS, 2003, 63 (05) : 523 - 523
12345